NBIX vs STEM · P/E 45, rev $2.36B vs rev $144.6M
Neurocrine Biosciences Inc (NBIX) versus Stem Inc (STEM) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Stem Inc (STEM) is a utilities - renewable company listed on US.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported STEM revenue for 2024-12-31 was $144.6M. Net income was -$854.0M. Revenue was down 68.7% from 2023-12-31 to 2024-12-31. STEM currently screens at market cap $82.1M.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. STEM currently screens at market cap $82.1M.
Not investment advice. Open the NBIX and STEM stock pages for the full models.
Not investment advice.